Riskpilot← Back to searchSign inGet full accessINHIBIO AS
ASActiveOrg 911637979Tollbugata 24, 0157 OsloForskning og utviklingsarbeid innen bioteknologi · NACE 72110Est. 20130 employees
Revenue 2021
NOK 3,5M
+12% vs 2020
EBITDA margin
-49.6%
-95% vs 2020
Equity ratio
-36.5%
Financial strength
Net profit 2021
NOK -1,9M
-75% vs 2020
| Revenue | NOK 3,5M | +12% |
| EBITDA | NOK -1,7M | -95% |
| Net profit | NOK -1,9M | -75% |
| Total assets | NOK 4,8M | +48% |
| Equity | NOK -1,7M | -79% |
| Employees | 0 | — |
Legal name
INHIBIO AS
Org number
911637979
Legal form
Aksjeselskap
NACE code
72110 · Forskning og utviklingsarbeid innen bioteknologi
Founded
7. mars 2013
Share capital
NOK 137 324 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikle, markedsføre og selge biofilm-relaterte produkter, metoder og tjenester samt delta i virksomhet med beslektet type aktivitet. Selskapet kan eie aksjer i andre selskaper.
Address
Tollbugata 24, 0157 Oslo
Phone
+4790672911
Email
post@inhibio.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2 227 | 3 559 | 2 407 | 3 104 | 3 485 |
| Staff expenses | −545 | −672 | −672 | −1 150 | −1 420 |
| EBITDA | −4 005 | −922 | −639 | −887 | −1 729 |
| Depreciation & amort. | −0 | −0 | −0 | −3 | −16 |
| EBIT | −4 005 | −922 | −639 | −890 | −1 745 |
| Net financials | −139 | −260 | −349 | −191 | −147 |
| Profit before tax | −4 144 | −1 182 | −989 | −1 081 | −1 891 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 144 | −1 182 | −989 | −1 081 | −1 891 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 528 | 2 839 | 1 677 | 3 224 | 4 774 |
| Equity | −4 973 | −6 155 | −7 144 | −974 | −1 745 |
| Long-term debt | 3 062 | 6 172 | 7 401 | 350 | 2 731 |
| Short-term debt | 2 440 | 2 822 | 1 420 | 3 848 | 3 788 |
| Total debt | 5 501 | 8 993 | 8 821 | 4 198 | 6 519 |
EBITDA margin
-49.6%
This company
15.8%
Market median
-414% vs market
20172021
Equity ratio
-36.5%
This company
38.2%
Market median
-196% vs market
20172021
Return on equity
-189149800.0%
This company
18.4%
Market median
-1027988143% vs market
20172021
Net profit margin
-54.3%
This company
8.1%
Market median
-770% vs market
20172021
Asset turnover
0.73×
This company
1.12×
Market median
-35% vs market
20172021
Debt / equity
3.74×
This company
0.62×
Market median
-503% vs market
20172021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
KH Chief Executive Officer | Chief Executive Officer | 2016 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2016 | |
| Chairman | 2016 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of INHIBIO AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kim Hjalmar Heglund | Chief Executive Officer | 0 companies |
| Rune Sørum | Board of Directors | 0 companies |
| Jørgen Andre Nilsen | Chairman | 0 companies |